POLARIS NN9490-8266
Efficacy and safety of amycretin on morbidity and mortality compared to placebo in people with heartfailure with preserved or mildly reduced ejection fraction and obesity.
- Stadium
- inclusie
- Middel
- Amycretin
- Populatie
- Hartfalen
- Fase
- III
- First Patient In
- 11 mei 2026
- Last Patient In
- 21 april 2028
- Last Patient Last Visit
- 22 juni 2029
Inclusieperiode, nog 701 dagen over
National Lead
Meems
Studiedirecteur
dr. S. Koudstaal
Cardioloog
Contact Kantoor
